Compare BLCO & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | STVN |
|---|---|---|
| Founded | 1853 | 1949 |
| Country | Canada | Italy |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | 2022 | 2021 |
| Metric | BLCO | STVN |
|---|---|---|
| Price | $16.90 | $16.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 2 |
| Target Price | $17.31 | ★ $23.75 |
| AVG Volume (30 Days) | 351.7K | ★ 567.7K |
| Earning Date | 02-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 0.37% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $4,976,000,000.00 | $1,373,219,524.00 |
| Revenue This Year | $8.06 | $8.42 |
| Revenue Next Year | $5.79 | $9.61 |
| P/E Ratio | ★ N/A | $28.91 |
| Revenue Growth | 6.23 | ★ 6.97 |
| 52 Week Low | $10.45 | $16.30 |
| 52 Week High | $18.14 | $28.00 |
| Indicator | BLCO | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 28.57 |
| Support Level | $16.74 | $16.30 |
| Resistance Level | $17.15 | $19.94 |
| Average True Range (ATR) | 0.39 | 1.03 |
| MACD | -0.08 | -0.36 |
| Stochastic Oscillator | 15.18 | 11.75 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.